

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.4)*

IDEC PHARMACEUTICALS CORPORATION

(Name of Issuer)

Common Stock, No Par Value

(Title of Class of Securities)

004493701

(CUSIP Number)

Donald F. Parman, SmithKline Beecham Corporation
One Franklin Plaza, Philadelphia, PA 19102
Telephone 215-751-7633

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

March 7, 1997

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b) (3) or (4), check the following box / /.

Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP NO. 857304100

PAGE 2 OF 6 PAGES

This Amendment No. 4 amends and supplements the Statement on Schedule 13D manually filed with the Securities and Exchange Commission (the "Commission") on

April 24, 1995 (the "Initial Statement") filed jointly by SmithKline Beecham plc, SmithKline Beecham Corporation, and S.R. One, Limited; Amendment No. 1 electronically filed on September 26, 1996; Amendment No. 2 electronically filed on December 13, 1996; and Amendment No. 3 electronically filed on March 3, 1997 with respect to ownership of securities of IDEC Pharmaceuticals Corporation.

The undersigned hereby amends and supplements Item 5 of the Initial Statement by the following information (capitalized terms used herein without definition shall have the same meaning as set forth in the Initial Statement.) Since the reporting person now holds less than 5% with this filing, further reporting under Schedule 13-D is no longer required.

3

SCHEDULE 13D

CUSIP NO. 0004493701

Page 2 of 5 Pages

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

SmithKline Beecham Corporation
23-1099050

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) / /
(b) / /

3 SEC USE ONLY

4 SOURCE OF FUNDS*

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E)

/ /

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Pennsylvania

7 SOLE VOTING POWER
NUMBER OF
SHARES

638,360

BENEFICIALLY

OWNED BY 8 SHARED VOTING POWER
EACH

REPORTING PERSON

None

WITH 9 SOLE DISPOSITIVE POWER

638,360

10 SHARED DISPOSITIVE POWER

None

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

638,360

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*

/ /

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

3.5%

14 TYPE OF REPORTING PERSON*

Item 1. Security and Issuer.

Item 2. Identity and Background.

Item 3. Source and Amount of Funds or Other Consideration.

Item 4. Purpose of Transaction.

Item 5. Interest in Securities of the Issuer.

(a) Amount and Percent Beneficially Owned

Registered Name	No. of Shares	Percent
SmithKline Beecham Corporation	638,360	3.5%

(b)

(c) The reporting persons sold 467,500 shares of Common Stock in the open market in the following manner:

Registered Name	Transaction Date	Number of Share	Price Per Share
SmithKline Beecham Corporation	March 4, 1997	30,000	24.50
SmithKline Beecham Corporation	March 5, 1997	15,000	24.50
SmithKline Beecham Corporation	March 6, 1997	12,500	24.50
SmithKline Beecham Corporation	March 6, 1997	7,500	24.625
SmithKline Beecham Corporation	March 7, 1997	40,000	24.875
SmithKline Beecham Corporation	March 7, 1997	40,000	25.00
SmithKline Beecham Corporation	March 7, 1997	10,000	25.25
SmithKline Beecham Corporation	March 7, 1997	10,000	25.375
SmithKline Beecham Corporation	March 7, 1997	25,000	25.50
SmithKline Beecham Corporation	March 7, 1997	12,500	25.625
SmithKline Beecham Corporation	March 7, 1997	5,000	25.75
SmithKline Beecham Corporation	March 7, 1997	45,000	25.875
SmithKline Beecham Corporation	March 10, 1997	12,500	26.125
SmithKline Beecham Corporation	March 11, 1997	165,000	29.50
SmithKline Beecham Corporation	March 11, 1997	10,000	29.625
SmithKline Beecham Corporation	March 11, 1997	25,000	30.00
SmithKline Beecham Corporation	March 14, 1997	2,500	28.50

		467,500	

(d)

(e)

Item 6. Contracts, Arrangements, Understandings or
Relationship With respect to Securities of the Issuer.

Item 7. Materials to be Filed as Exhibits.

6

Page 5 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and
belief, the undersigned certifies that the information set forth in the
Statement is true, correct and complete.

SMITHKLINE BEECHAM CORPORATION

By: /s/Donald F. Parman

Donald F. Parman
Secretary

DATED: March 17, 1997